A Phase 2 interventional study of ABX464 and Placebo oral capsule in Ulcerative Colitis, sponsored by Abivax S.A.. Completed at 19 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-06-03.
Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 221 studies in Colitis, Ulcerative with a site in Poland — 36 open to participants now, 65 under way, 31 of them phase 3. Colitis, Ulcerative · Poland.
Among the 221 studies in Colitis, Ulcerative with a site in Poland, this one is the 198th largest by enrollment of the 215 interventional ones that give a count, is one of 7 that started in 2017, is one of 104 in phase 2, and was the 82nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →36 of the 221 studies in Colitis, Ulcerative with a site in Poland are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Poland, United States, Canada and 9 more countries
Ages 18–75
Hoffmann-La Roche · Sites in Poland, United States, Belgium and 2 more countries
Ages 18–60
Pfizer · Sites in Poland, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in Poland, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Poland, United States, Belgium and 7 more countries
Ages 18–80
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
221 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 116 · Phase 3 93 · Phase 4 4
First in 2005; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 196 across the 215 interventional studies, 389 across the 6 observational. Of the 154 that completed or were terminated, 121 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
212 of 221 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 8 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
21 of the studies in Colitis, Ulcerative with a site in Poland that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 21 to your calendar (.ics) → With an account.
Among the 221 studies in Colitis, Ulcerative with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month follow-up period.
This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month follow-up period.
Eligible subjects will be randomized according to a 2/1 ratio in two different groups of treatment. Randomized subjects who will receive 50 mg ABX464 orally once daily for 56 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 50 mg of ABX464 orally once daily for 56 days.
Drug: ABX464
Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.
Drug: Placebo oral capsule
ABX464 is a new Anti-inflammatory drug
Placebo matching with ABX464
Number of Subjects With Treatment-emergent Adverse Events
Number of treatment-emergent adverse events in the ABX464 treated subjects compared to placebo
Time frame: Week 8
Clinical Remission
Percentage of subjects receiving ABX464 with clinical remission according to the Total Mayo Score at Week 8 compared to placebo (primary efficacy endpoint)
Time frame: Week 8
Fecal Calprotectin
Percentage of patients with fecal calprotectin levels \> 50µg/g at Week 8 compared to placebo
Time frame: Week 8
Total Mayo Score
Change from baseline in Total Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 12; 12 being the worst score) - 4-component Scale: Rectal bleeding, Stool frequency, Mucosal appearance and Physician Global Assessment
Time frame: Week 8
Change in Partial Mayo Score
Change from baseline in Partial Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 9, with 9 indicating the worst score. It is a three-component scale assessing rectal bleeding, stool frequency, and the physician's global assessment.
Time frame: Week 8
| Milestone | ABX464 Treatment Arm | ABX464 Matching Placebo Treatment Arm |
|---|---|---|
| Started | 23 | 9 |
| Completed | 21 | 9 |
| Not completed | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Number of treatment-emergent adverse events in the ABX464 treated subjects compared to placebo
| Participants | ABX464 Treatment Arm | ABX464 Matching Placebo Treatment Arm |
|---|---|---|
| Number of Subjects With Treatment-emergent Adverse Events | 18 | 5 |
Percentage of subjects receiving ABX464 with clinical remission according to the Total Mayo Score at Week 8 compared to placebo (primary efficacy endpoint)
| Participants | ABX464 Matching Placebo Treatment Arm | ABX464 Treatment Arm |
|---|---|---|
| Clinical Remission | 7 | 1 |
Percentage of patients with fecal calprotectin levels \> 50µg/g at Week 8 compared to placebo
| Participants | ABX464 Treatment Arm | ABX464 Matching Placebo Treatment Arm |
|---|---|---|
| Fecal Calprotectin | 15 | 8 |
Change from baseline in Total Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 12; 12 being the worst score) - 4-component Scale: Rectal bleeding, Stool frequency, Mucosal appearance and Physician Global Assessment
| score on a scale | ABX464 Treatment Arm | ABX464 Matching Placebo Treatment Arm |
|---|---|---|
| Total Mayo Score | -4.6 ± 2.8 | -2.1 ± 2.5 |
Change from baseline in Partial Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 9, with 9 indicating the worst score. It is a three-component scale assessing rectal bleeding, stool frequency, and the physician's global assessment.
| units on a scale | ABX464 Treatment Arm | ABX464 Matching Placebo Treatment Arm |
|---|---|---|
| Change in Partial Mayo Score | -3.9 ± 2.2 | -1.8 ± 2.0 |
Collected over From baseline up to 4 weeks post last dose of study drug (up to 63 Days). Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABX464 | 0/23 (0%) | 0/23 (0%) | 18/23 (78.3%) |
| Placebo | 0/9 (0%) | 1/9 (11.1%) | 5/9 (55.6%) |
| Event | ABX464 | Placebo |
|---|---|---|
| Nephrolithiasis left sideRenal and urinary disorders | 0/23 | 1/9 |
| Event | ABX464 | Placebo |
|---|---|---|
| HypophosphataemiaMetabolism and nutrition disorders | 1/23 | 2/9 |
| Abdominal painGastrointestinal disorders | 4/23 | 1/9 |
| HeadacheNervous system disorders | 4/23 | 0/9 |
| Abdominal pain upperGastrointestinal disorders | 3/23 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 0/23 | 1/9 |
| NasopharyngitisInfections and infestations | 1/23 | 1/9 |
| Iron deficiencyMetabolism and nutrition disorders | 1/23 | 1/9 |
| NephrolithiasisRenal and urinary disorders | 0/23 | 1/9 |
| Renal colicRenal and urinary disorders | 0/23 | 1/9 |
| NauseaGastrointestinal disorders | 2/23 | 0/9 |
The safety analysis set included all participants who received at least 1 dose of ABX464.
| Age, Categorical(Participants) | ABX464 Treatment Arm | ABX464 Matching Placebo Treatment Arm | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 19 | 9 | 28 |
| >=65 years | 4 | 0 | 4 |
| Sex: Female, Male(Participants) | ABX464 Treatment Arm | ABX464 Matching Placebo Treatment Arm | Total |
|---|---|---|---|
| Female | 11 | 1 | 12 |
| Male | 12 | 8 | 20 |
| Race (NIH/OMB)(Participants) | ABX464 Treatment Arm | ABX464 Matching Placebo Treatment Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 23 | 9 | 32 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2017 to primary completion in Jul 2018, 8 months.
Results were first posted in Feb 2023, 4 years 6 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 8 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464